ReviewCancers2023
Topical Imiquimod in Primary Cutaneous Extramammary Paget's Disease: A Systematic Review.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Treatment Strategies for Extramammary Paget Disease: A Narrative Review of Current Status and Future Directions.Cancers · 2026Review
- Vulvar extramammary Paget's disease with clitoral involvement: case series highlighting the role of topical treatment.International journal of women's dermatology · 2026Article
- Innovative and Customized 3-Dimensional-Printed Mold Brachytherapy Treatment of Genital Extramammary Paget's Disease.Advances in radiation oncology · 2026Article
- Extramammary Paget's disease: when is enough, enough?International journal of women's dermatology · 2025Article
- Review
- Perianal Paget's Disease: A Challenge of Surgical Margins in Uncommon Clinical Presentations.Cureus · 2025Article
- Assessing mortality risk and causes in extramammary Paget's disease: insights from a population-based study.Translational cancer research · 2025Article
- Case Report: Surgical androgen deprivation therapy for prostate cancer in a patient with concurrent scrotal paget's disease.Frontiers in oncology · 2025Article
- Erythematous plaque in the axilla.JAAD case reports · 2024Article
- Non-surgical management of recurrent Paget's disease of the vulva: A case report.Gynecologic oncology reports · 2024Article
- Rectal Adenocarcinoma With Pagetoid Spread: A Novel Entity.Case reports in gastrointestinal medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extramammary Paget's disease (EMPD) is subclinical in extent and multifocal in nature. There is no global consensus for treatment, so its management represents a challenge in clinical practice. Therefore, we conducted a systematic review through the main electronic databases to assess the effectiveness of topical imiquimod in cutaneous EMPD and to discuss its management. Finally, 24 studies involving a total of 233 EMPD patients treated with topical imiquimod were selected. The topical imiquimod response rate was 67%, and the complete response (CR) rate was 48%. Patients were treated with a three-four times a week regimen in most cases, ranging between 2 to 52 weeks. In addition, imiquimod was applied as an adjunctive treatment in 21 patients, achieving a CR rate of 71%. Consequently, imiquimod therapy could achieve a good response ratio as a first-line treatment, as adjuvant and neo-adjuvant therapy, and as a treatment for recurrent disease. The heterogeneity between studies and the lack of a control arm made it impossible to conduct a meta-analysis. To improve the quality of evidence on EMPD, multicenter studies are essential to collect a larger number of patients and, consequently, obtain high-quality evidence to standardize treatment. The Prospero registration number is CRD42023447443.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.